Small trials with G-CSF treatment in ALS patients demonstrated excellent tolerability and safety (23–25), with modulation of immune parameters (26), and possible minor benefits detected by neuroimaging (27). The gene discussed is CSF3; the disease is amyotrophic lateral sclerosis.